Rezolute (RZLT) EPS (Basic) (2012 - 2026)

Rezolute (RZLT) posted EPS (Basic) of -$0.2 for Q1 2026, up 17.48% sequentially from -$0.24 in Q4 2025, and up 41.9% YoY from -$0.14 in Q1 2025.

Analysis

Rezolute (RZLT) EPS (Basic) (2012 - 2026) Analysis & Trends

Rezolute has reported EPS (Basic) for 15 years, with the latest figure at -$0.2 in Q1 2026.

Quarterly EPS (Basic) rose 41.9% year-over-year to -$0.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.57 (up 3.3% YoY) and the FY2025 annual result came in at -$0.98, up 26.39% from the prior year.
EPS (Basic) rose to -$0.2 in Q1 2026 per RZLT's latest filing, from -$0.24 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.2 in Q2 2023 and troughed at -$0.89 in Q3 2025.
A 5-year average of -$0.4 and a median of -$0.35 in 2025 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2024: EPS (Basic) jumped 99.93% in 2022, then sank 85.4% in 2024.
Over 5 years, EPS (Basic) stood at -$0.28 in 2022, then decreased by 0.68% to -$0.28 in 2023, then slumped by 80.37% to -$0.5 in 2024, then soared by 51.2% to -$0.24 in 2025, then advanced by 17.48% to -$0.2 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.2, -$0.24, and -$0.89 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	139.27 Bn	131.42 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.55 Bn	77.56 Bn	3.93 Bn	12.62
3	Argenx Se	63.45 Bn	58.27 Bn	1.37 Bn	7.70
4	Moderna	57.73 Bn	52.59 Bn	52.00 Mn	-1.96
5	Revolution Medicines	44.08 Bn	44.08 Bn	-	-3.06
6	BeOne Medicines	39.95 Bn	34.85 Bn	1.53 Bn	2.12
7	Alnylam Pharmaceuticals	35.14 Bn	31.84 Bn	992.69 Mn	1.23
8	Royalty Pharma	28.44 Bn	27.60 Bn	-	0.18
9	Insmed	27.32 Bn	26.16 Bn	358.27 Mn	-0.06
10	Rezolute	474.94 Mn	474.94 Mn	-	-0.16

Historic Data

Download Data